Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeae.

Hadad, R.; Cole, M.; Ebeyan, Samantha; Jacobsson, S.; Tan, L.; Golparian, D.; M Erskine, Simon; Day, M.; Whiley, D.; Unemo, M.; Abad Torreblanca, Raquel; R. Ásmundsdóttir, L.; Balla, E.; De Baetselier, I.; Berçot, Béatrice; Bergheim, Thea; Borrego, M.; Buder, S.; Cassar, Roberto; Cole, M.; V. van Dam, A.; Eder, C.; Hoffmann, S.; Hunjak, B.; Jeverica, S.; Kirjavainen, V.; Maikanti-Charalambous, Panayiota; Miriagou, V.; Młynarczyk-bonikowska, B.; Pakarna, Gatis; Pavlík, P.; Perrin, M.; Pett, Joseph; Stefanelli, P.; Templeton, K.; Unemo, M.; Viktorova, Jelena; Zákoucká, H.

doi:10.1093/jac/dkaa381

Public

Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeae.

Shared by NobleBlocks on Sep 15, 2020 • 12:00 AM UTC

Authors:

R. Hadad

M. Cole

Samantha Ebeyan

Abstract

BACKGROUND Accurate molecular assays for prediction of antimicrobial resistance (AMR)/susceptibility in Neisseria gonorrhoeae (Ng) can offer individualized treatment of gonorrhoea and enhanced AMR surveillance. OBJECTIVES We evaluated the new ResistancePlus® GC assay and the GC 23S 2611 (beta) assay...

Subject

Medicine

Biology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!